Measuring flu vaccine immunity in COVID-19 patients
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
This study looks at how well the flu vaccine works in people aged 13 to 64 who have had COVID-19, comparing their immune responses to those who haven't had the virus.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 230 (estimated) |
| Ages | 9 Years to 64 Years |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT04579588 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the immunity response to the flu vaccine over time in individuals aged 13 to 64 who have previously been diagnosed with COVID-19. Participants will include both those with COVID-19 and a control group without the virus, allowing for a comparative analysis of immune responses. The study will focus on patients who may also have other medical conditions such as obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. By monitoring these responses, the study seeks to understand how prior COVID-19 infection influences flu vaccine efficacy.
Who should consider this trial
Good fit: Ideal candidates include adults and children aged 13 to 64 who have been diagnosed with COVID-19 at least two months prior to enrollment.
Not a fit: Patients who have received the influenza vaccine within the last four months or those with immunodeficiency or autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into optimizing flu vaccination strategies for COVID-19 survivors, potentially improving their immunity and health outcomes.
How similar studies have performed: While studies on vaccine responses in COVID-19 patients are emerging, this specific focus on flu vaccine immunity in this population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 9 through 64 years * Diagnosed with COVID-19 at least 2 months prior enrollment * Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms * Patients without COVID-19 diagnosis for controls Exclusion Criteria: * Received the influenza vaccine less than 4 months ago * Pregnant or lactating * Patients with special risks attendant to venipuncture * Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment * Contraindication to the flu vaccine * Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Sayantani Sindher, MD — Stanford University
- Study coordinator: SNP Center Inquiry
- Email: snpcenterallergy_inquiry@stanford.edu
- Phone: (650) 521-7237
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.